SCHEMBL27152162

SCHEMBL27152162

O=Cc1ccc2nc(N3C[C@H]4C[C@@H](C3)O4)ccc2c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 7/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HTR3A P46098 2/20 0.35
▸ HRH4 Q9H3N8 1/20 0.35
▸ HTR3E A5X5Y0 1/20 0.34
▸ HTR3B O95264 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ THPO P40225 1/20 0.34
▸ HTR3D Q70Z44 1/20 0.34
▸ HTR3C Q8WXA8 1/20 0.34
▸ ACACB O00763 2/20 0.33
▸ CYP2A6 P11509 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27138785 0.83 HCRTR1 (0.37) HRH3ALDH1A1HTR3AHRH4HTR3E
SCHEMBL27109011 0.80 PDE10A (0.46) HRH3HTR3AHRH4ACACB
SCHEMBL27148782 0.79 HTR3A (0.38) HTR3AHRH4
SCHEMBL27138757 0.78 ALDH3A1 (0.51) ALDH1A1KDM4EGAAHTR3AHRH4
SCHEMBL27144957 0.76 PDE10A (0.43) HRH3ALDH1A1KDM4EHTR3AHRH4
SCHEMBL27109006 0.76 HRH3 (0.44) HRH3ALDH1A1HTR3AHRH4HTR3E
SCHEMBL27108980 0.75 HTR3A (0.63) HRH3ALDH1A1KDM4EHTR3AHRH4
SCHEMBL27143829 0.75 BRD4 (0.34) HRH3CYP2A6
SCHEMBL27139164 0.75 HTR3A (0.37) HRH3ALDH1A1KDM4EHTR3AHRH4
SCHEMBL27145061 0.74 HTR3A (0.45) HRH3ALDH1A1KDM4EHTR3AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 — — EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 — — CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 — — US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 HRH3 4094/4885ALDH1A1 3122/4885KDM4E 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback